ArticleMolecular and cellular biology1988
Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine.
Article in Molecular and cellular biology, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 107 citations in OpenAlex.
- Review
- Current status and new directions for hepatocellular carcinoma diagnosis.Liver research (Beijing, China) · 2024Review
- The Current Status of the Liver Liquid Biopsy in MASH Related HCC: Overview and Future Directions.Biomolecules · 2023Review
- Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.International journal of molecular sciences · 2022Review
- The prognostic value of arginase-1 and glypican-3 expression levels in patients after surgical intrahepatic cholangiocarcinoma resection.World journal of surgical oncology · 2021Article
- Glypicans and Heparan Sulfate in Synaptic Development, Neural Plasticity, and Neurological Disorders.Frontiers in neural circuits · 2021Review
- Glypican 3-Targeted Therapy in Hepatocellular Carcinoma.Cancers · 2019Review
- Apatinib-loaded lipid nanobubbles combined with ultrasound-targeted nanobubble destruction for synergistic treatment of HepG2 cells in vitro.OncoTargets and therapy · 2018Article
- Can glypican-3 be a disease-specific biomarker?Clinical and translational medicine · 2017Review
- Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.Oncotarget · 2016Article
- Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.World journal of gastroenterology · 2016Review
- Article
- Biomarkers for hepatocellular carcinoma.Clinical journal of gastroenterology · 2012Article
- Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2011Review
- Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.Anti-cancer agents in medicinal chemistry · 2011Review
- Glypican-3: a new target for cancer immunotherapy.European journal of cancer (Oxford, England : 1990) · 2011Review
- Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas.Cancer science · 2009Article
- Glypicans.Genome biology · 2008Review
- Methylation analysis of the glypican 3 gene in embryonal tumours.British journal of cancer · 2004Article
- Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells.Oncogene · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the isolation of a cDNA clone corresponding to a transcript that is accumulated differentially in rat intestine during development. Clone OCI-5 was selected from the rat intestinal cell line IEC-18, which represents primitive intestinal epithelial crypt cells. Expression was high in rat fetal intestine between 15 and 19 days of development and thereafter was progressively down regulated, becoming undetectable after weaning. Clone OCI-5 detected homologous sequences in human and murine cells. In particular, a high level of expression was detected in CaCo-2, a human colon carcinoma cell line, which is known to express molecules characteristic of fetal small intestinal cells. Expression of a homologous gene was also detected in F9 murine teratocarcinoma cells when they were induced to differentiate into parietal or visceral endodermlike cells. When IEC-18 cells were transformed by activated H-ras or v-src genes, expression of clone OCI-5 was suppressed; the degree of down-regulation correlated with the extent of morphological change induced in the transformed IEC-18 cells. The sequence of clone OCI-5 showed an open reading frame that was capable of encoding a protein of 597 amino acids, but no strong homology was found with any of the proteins registered in the protein sequence data base.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.